Table 2.

Direct labeling of proteins and antibodies with ¹²⁴I.

Method	Imaging target	Antibody	Results	Reference
Iodogen®	HER2	Anti-HER2	RCY: 13.8–18.8%;	[98]
			AS: 33-102 MBq/mg,
	positive tumours	Diabody	RCP: >93.5%
	Apoptotic cells	Annexin V	RCY: 20–70%	[99,100]
		Annexin V	RCY: 6–12%	[101,102,103]
			RCP: 95%
		MBP-Annexin V		[104]
	CD44v6	cMAb U36	RCY: 72%	[105,106]
	positive cells		RCP: >97%
			AS: 32.6 MBq/mg
	squamous cell
	carcinoma
	CEA	Anti-CEA	RCY: 33–88%	[107]
		mini- and diabodies
CAT-method	Apoptotic cells	Annexin V	RCY: 4-6%,	[103]
			RCP: >99%,
			AS: 8.6 GBq/µmol
	Human glioma	3F8 mAb	RCY: >90%	[108,109,110]
		A33 mAb	RCY: 55%	[110]
	Colon cancer	huA33 mAb	RCY: 40%,	[111]
			RCP >98%,
			AS: 7.4 MBq/mg
	CEA	mAb CE-25,	RCY: 70–80%,	[112]
		CE 4-8-13
	Ovarian cancer	MX35 or MH99	RCY: >87%	[113]
NBS-method	Breast cancer	C-erbB2	RCY: 96%	[114]
		HMFG1		[115]

RCY = radiochemical yield; RCP = radiochemical purity; A_S = specific activity.